A process for the preparation of oxindole derivative (Ziprasidone hydrochloride) of formula (I) comprising reacting compound of formula (II) with Sn and HC1 to give compound of formula (III) in a single step which is converted into compound of formula IV which is a key intermediate for the preparation of compound of...

The present invention discloses an improved process for the preparation of racemic 6, 6-dimethyl-3-azabicyclo-[3.1.0]-hexane of formula I and its salts. The invention relates to the compounds of formulae I and II. The compound of formula I is a key raw material for the preparation of key intermediate (1R, 2S, 5S) - ...

The present invention provides an improved processes having practical utility for preparing 2-oxindoles of formula I comprising preparation of 2-nitroarylmalonate diester of formula II as first intermediate and subsequent insitu reductive cyclisation using metal acid combination and its modified work-up to form comp...

The present invention relates to an improved process for the preparation of pharmaceutically acceptable salts of milnacipran by mutual acid radical exchange.

The subject invention relates to a continuous green process for the preparation of alkyl-(aminophenyl)-carbamate of formula-I comprising contacting substrate diaminobenzene (also known as phenylenediamine) of formula-II with substrate alkyl haloformate of formula-III in water as a green reaction medium without using...

: 4-Substituted-1,4-dihydropyridines of formula I are prepared by a cycloaddition reaction in which the cyclization is driven to completion at ambient temperature optionally in water without any catalyst. For exemplary purposes, the invention is described in particular detail with respect to the preparation of felod...

The present invention provides an efficient process for the preparation of substantially pure N-carbamoyl-tert leucine of formula I which is a key intermediate for the preparation of various therapeutic agents or a therapeutic agent precursor used as ("HCV") protease inhibitors. The present invention relates to a pr...

Disclosed herein is an efficient process for the preparation of N-benzyl 4- formyl piperidine of formula-l which is a key intermediate for the preparation of acetylcholinesterase inhibitor donepezil hydrochloride (I), chemically known as (+-)-2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)- 4-piperidinyl]methyl]-...

The present invention relates to a new process for the preparation of 1-[4-[3-[4-(6-fluoro- l,2-benzisoxazol-3-yl)- l-piperidinyl]propoxy]-3-methoxyphenyl]- ethanone (Iloperidone) and salts thereof The synthetic process comprises the reaction between itself 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole of formula II ...

Present invention is to provide in-situ preparation of intermediates, Dronedarone and pharmaceutically acceptable salts thereof in higher yield and purity starting from 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran. The said process is carried out without isolation and purification of intermediates and is particu...

Disclosed herein is an improved process for the preparation of Benzoxazole of formula I; a key intermediate for the preparation of MK-4305 via an advanced intermediate of formula II depicted herein above. The process comprises chip and commercially available starting materials using novel chemistry to synthesize ben...

The present invention relates to an advanced and improved process over the prior art for the preparation of 4-fluoro-a-[2-methyl-l-oxopropyl]-y-oxo-N-P-diphenylbenzenebutanamide of the formula I commercially referred as DKT III, a key intermediate for the synthesis of Atorvastatin and pharmaceutically acceptable sal...

This invention is directed to an efficient and economical process for the preparation of substituted amine hydro halides of formula I, particularly to N.N-dimethylamine hydrochloride of formula II and hydrates thereof; and its further use for making various APIs.

Disclosed herein is an improved, economical and ecofriendly single step hydrogenation process using raney nickel for the preparation of 2-oxindoles of formula I preferably IA with less sulphated ash, high HPLC assay and high HPLC purity.

Disclosed herein is an efficient and industrially viable process for the preparation of stable crystalline Form-I of Lamivudine comprising heating lamivudine in solid powdered, amorphous or any other crystalline form in an alcoholic solvent preferably methanol upto its reflux temperature to obtain a suspension and t...

Disclosed herein are two different crystalline polymorphic forms of retigabine dihydrochloride of formula I referred as form I and form II. These forms are characterized by their 20 values on XRD and their crystal shapes. It also describes the process for the preparation of these forms.

Disclosed herein is an efficient and economical process for the preparation of 3-Benzyloxybenzenethiol of formula-I which is a key intermediate for the preparation of pharmaceutical drugs. R" is hydrogen, halogen, trihalomethyl, lower alkoxy having 1-4 carbon atoms, lower alkyl having 1-7 carbon atoms, substituted ...

The present invention relates to salts of (S)-(+)-N-methyl-3-(l-naphthalenyloxy)-3-(2-thiophenyl) propanamine more particularly Lewis acid salts of duloxetine of the formula I and further it relates to a process of preparation of salts of (S)-(+)-N-methyl-3-(l-naphthalenyloxy)-3-(2-thiophenyl) propanamine, more par...

The invention relates to an improved process for the preparation of flupirtine (I) and its pharmaceutically acceptable salts, especially of flupirtine maleate (IA), and pure crystal modification. A of flupirtine maleate.

Disclosed herein is an improved, commercially viable and industrially advantageous novel process for the preparation of Strontium ranelate of formula I chemically known as distrontium 5-[bis(2-oxido-2-oxoethyl)amino]-4-cyano-3-(2-oxido-2-oxoethyl)thiophene-2-carboxylate or 5-[bis(carboxymethyl)amino]-2-carboxy-4-cya...

N/A

A novel process for the preparation of 4-fluoro-α-[2-methyl-l-oxopropyl]-Y-oxo-N-p-diphenylbenzenebutanamide also known as 2-[2-(4-fluorophenyl)-2-oxo-l-phenylethyl]-4-niethyl-3-oxo-pentanoic acid phenylamiclc of the formula I containing about 0.1% or less of α-[2-methyl-l-oxopropyl]-y-oxo-N-β-diphenylbenzene butana...

A process for the preparation of Pregna-1, 4-diene – 3,20-dione-16,17-acetal-21 esters of Formula (I) by green process chemistry unsing a combination of an ionic liquid, organic solvent optionally in the presence of an inorganic nitrite. Wherein R amd R’ represent a) R=H,R-cyclohexyl or b)R=CO-CH(CH3)2,R’=cyclohexyl...

A process for the preparation of alkyI-(R)-4-cyano-3-hydroxybutyrate of Formula I in high optical purity of about 99.9%, having S enatiomer less than about 0.1% and low moisture content of about 0.16-0.19%, while minimizing the level of hydrogen cyanide production, which comprises the steps of: i. Providing alk...

The present invention provides a process for producing a compound of formula I which is an important pharmaceutical intermediate, particularly an intermediate of an carbapeneum antibiotics. Formula I Ri is selected from the group of H, C1-C4 alkyl group, Secondary alcoholic group, and Secondary thioalcoholic group...

Disclosed herein is a process for preparation of imatinib free base which comprises condensing 4-Methyl-N-(4-pyridin-3-yl-pyrimidin-2-yl)-benzene-l,3-diamine with 4-(4-Methyl-piperazin-l-ylmethyl)-benzoic acid ester in the presence of base including organic bases and inorganic bases in an organic solvent to form ima...

The present invention provides a process for producing a 5-hydroxy-3-oxo pentatonic acid derivative of formula I which is an important pharmaceutical intermediate, particularly an intermediate of an HMG-COA reductase inhibitor.

A novel process for the preparation of stable clopidogrel base of formula I or its alcoholic solution/suspension having improved stability during storage over extended periods of time suitable for pharmaceutical use and as an intermediate for making pharmaceutically accepted salts and for its use for the preparation...

Disclosed herein is an novel process for the preparation of Gemcitabine Hydrochloride (2"-deoxy-2",2"-difluorocytidine hydrochloride) of the formula I comprising asymmetrical chemical reaction between difluoroacetic acid coupled with chiral auxiliary and protected glycerafdehydes to obtain a sterospecific isomer of ...

An improved one pot process for preparing 2-deoxy-D-erythro-2,2-difluoro-pentafuranose-1-ulose-3,5-dibenzoate of Formula (I) comprising hydrolysis of (erythro:threo) alkyl-3-dioxalan-4-yl-2,2-difluoro-3-hydroxy propionate of Formula (III) where alkyl group is having C1-C4 number of Carbon atoms using a mild acid and...

A process for the preparation on N-methyl- aryloxy-propanamine derivatives of the formula I and salts thereof. The invention also relates to the preparation and use novel intermediate of the formula XII. The invention also relates to the process of further conversion of novel intermediate into N-methyl- aryloxy prop...

A process for the preparation of anhydrous rare earth metal halides comprising forming slurry of said rare earth metal hydrates in aromatic hydrocarbon and removal of water by azeotropic distillation.

This invention concerns generally with a process for purifying crude pharmaceutical compositions, wherein the crude pharmaceutical composition comprises a sodium salt of Montelukast and more particularly relates to a process for the production of pharmaceutically pure preparations of Montelukast sodium using sim...

The invention relates to process for the preparation of 2-amino-4-(4-fluorobenzylamino)-l-ethoxycarbonylaminobenzene generically known as Retigabine of the formula (I) and its pharmaceutically acceptable salts e.g. Formula IA, particularly to the modification over the prior art processes-I and II disclosed therein i...

The present invention relates to an improved, commercially viable and industrially advantageous process for the preparation of substantially pure strontium ranelate of formula I and hydrates thereof.

The present invention relates to an improved and commercially viable process for the resolution of racemic cis milnacipran of formula I and its pharmaceutically acceptable salts of formula II. The present invention comprises using racemic cis milnacipran or its pharmaceutically acceptable salts as starting material,...

The instant invention relates to an improved batch process for the preparation of formula I by cross Claisen condensation using lithium metal amine chemically represented as LiNH2 of formula II as lithium source over conventionally used n-butyl lithium, lithium diisopropylamide referred as LDA, lithium hexamethyldis...

ABSTRACT: The present invention relates to improved process for the preparation of a pyrrole derivative as a racemic mixture, an enantiomer, a diastereoisomer, a mixture thereof, a tautomer thereof or a pharmaceutically acceptable salt and hydrates thereof and also intermediates involved therein. Particularly inven...